Relationship Between Plasma Concentrations and Clinical Effects of Cariprazine in Patients With Schizophrenia or Bipolar Mania.
Population pharmacokinetic/pharmacodynamic modeling (via NONMEM) was used to describe longitudinal exposure-response relationships for total cariprazine (sum of cariprazine and its major active metabolites) in 2558 patients with schizophrenia or bipolar mania. Drug exposure metrics were explored for potential relationships with efficacy and safety endpoints. Total cariprazine exposures were significantly related to reductions in PANSS or YMRS total scores in schizophrenia or bipolar mania, respectively, via an Emax -type relationship. Typical steady-state plasma concentrations after 3 mg/d and 4.5 mg/d were associated with 50% of maximum typical reductions in PANSS and YMRS total scores, respectively. Time-weighted cariprazine exposures had significant relationships with the probability of common adverse events (AEs). Dose increase was associated with increased efficacy but was also associated with an increase in AEs. Results of these PK/PD analyses support that the recommended dose range (1.5-6 mg/d for schizophrenia and 3-6 mg/d for bipolar mania) provides an appropriate benefit-risk balance between cariprazine efficacy and safety.